Phathom Pharmaceuticals (PHAT) Key Ratios
$9.37
As on 01-Sep-2026 12:38EDT
Market cap
$743 Mln
Revenue (TTM)
$240 Mln
P/E Ratio
--
P/B Ratio
25.4
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 27.40 | 88.02 | 110.16 | -- | -- |
| EBIT | 82.99 | 95.75 | 86.16 | 20.69 | 12.08 |
| Net Profit | 42.11 | 76.81 | 69.99 | 13.55 | 6.62 |
| EPS | 43.28 | 79.93 | 73.04 | 19.57 | 11.46 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -7,989.16 | -7,989.16 | -14.87 | -87.45 | -474.76 |
| Net Margin
| -- | 7,140.60 | -41.34 | -- | -- |
| Return on equity
| 180.69 | 3,062.33 | -- | 63.97 | 204.89 |
| Return on Capital
| -1,625.26 | -1,031.88 | -- | 159.15 | -4,579.49 |
| Return on Assets
| -74.50 | -78.90 | -24.08 | -69.41 | -84.41 |
| Debt to Equity (x)
| -- | -- | -0.48 | -0.48 | -0.80 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
--
|
159.15
|
-4,579.49
|
-455.44
|
-212.89
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
--
|
63.97
|
204.89
|
273.21
|
14,877.58
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-24.08
Higher than Peers by 6.90
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
-24.08
|
-69.41
|
-84.41
|
-69.68
|
-111.63
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
-14.87
Higher than Peers by 68.75
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
-14.87
|
-87.45
|
-474.76
|
-23,405.28
|
--
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
-41.34
Higher than Peers by 51.33
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
-41.34
|
-126.35
|
-605.09
|
-29,558.94
|
--
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
110.16
Higher than Peers by 56.21
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
110.16
|
2.17
|
80.01
|
--
|
--
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
86.16
Higher than Peers by 86.96
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
86.16
|
41.62
|
-64.33
|
6.33
|
-24.31
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
69.99
Higher than Peers by 77.29
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
69.99
|
33.82
|
-65.84
|
-1.96
|
-37.42
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
73.04
Higher than Peers by 58.39
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
73.04
|
0.36
|
-0.20
|
0.18
|
-0.26
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
26.60
Higher than Peers by 36.77
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
26.60
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
-0.48
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
-0.48
|
-0.48
|
-0.80
|
-1.91
|
-1.30
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.00
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
0.00
|
0.00
|
0.00
|
-0.01
|
-0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.92
Lower than Peers by 3.89
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
1.92
|
1.73
|
4.20
|
10.25
|
6.12
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
1.87
Lower than Peers by 3.82
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
1.87
|
1.69
|
4.16
|
10.22
|
6.12
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-0.56
Higher than Peers by 1.53
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
-0.56
|
-2.25
|
-3.64
|
-3.80
|
-6.24
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
40.65
Higher than Peers by 21.51
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
40.65
|
44.62
|
70.22
|
240.03
|
--
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.58
Higher than Peers by 0.52
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
0.58
|
0.55
|
0.14
|
0.00
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
--
|
121.94
|
133.65
|
438.35
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
--
|
70.52
|
101.15
|
1,321.02
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
--
|
125.18
|
529.30
|
24,712.33
|
4,461.65
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
--
|
67.28
|
-294.50
|
-22,952.96
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
--
|
-5.54
|
-1.73
|
-2.32
|
-2.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
25.37
Higher than Peers by 20.19
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
25.37
|
-2.79
|
-2.27
|
-6.44
|
-6.20
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-2.20
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
-2.20
|
-8.57
|
-1.84
|
-1.42
|
-2.39
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
743
Higher than Peers by 597
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
743
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|